Bicara Therapeutics Files IPO Amendment

TL;DR

Bicara IPO filing updated. Looks like they're still aiming for the public markets.

AI Summary

Bicara Therapeutics Inc. filed an S-1/A amendment on September 11, 2024, for its initial public offering. The company, located at 116 Huntington Avenue, Suite 703, Boston, MA 02116, is seeking to register an unspecified number of shares. Claire Mazumdar is the CEO and the company's principal executive offices are in Boston, MA.

Why It Matters

This filing indicates Bicara Therapeutics is moving forward with its plan to become a publicly traded company, which could provide significant capital for its drug development programs.

Risk Assessment

Risk Level: medium — As a pre-IPO company in the biotech sector, Bicara Therapeutics faces inherent risks related to clinical trials, regulatory approval, and market acceptance.

Key Numbers

• 2834 — SIC Code (Pharmaceutical Preparations industry)
• 12/31 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• Bicara Therapeutics Inc. (company) — Registrant
• September 11, 2024 (date) — Filing date
• 116 Huntington Avenue, Suite 703, Boston, MA 02116 (location) — Principal executive offices
• Claire Mazumdar (person) — Chief Executive Officer
• 333-281722 (registration_number) — SEC registration number

FAQ

Key Financial Figures

• $16.00 — ial public offering price to be between $16.00 and $18.00 per share. We have applied t
• $18.00 — offering price to be between $16.00 and $18.00 per share. We have applied to list our

Filing Documents

• d821336ds1a.htm (S-1/A) — 2407KB
• d821336dex51.htm (EX-5.1) — 5KB
• d821336dex231.htm (EX-23.1) — 1KB
• d821336dexfilingfees.htm (EX-FILING FEES) — 30KB
• g821336g00a08.jpg (GRAPHIC) — 141KB
• g821336g00q02.jpg (GRAPHIC) — 217KB
• g821336g01r87.jpg (GRAPHIC) — 84KB
• g821336g05g18.jpg (GRAPHIC) — 84KB
• g821336g10k10.jpg (GRAPHIC) — 147KB
• g821336g10r10.jpg (GRAPHIC) — 194KB
• g821336g12w20.jpg (GRAPHIC) — 239KB
• g821336g14t99.jpg (GRAPHIC) — 148KB
• g821336g24l67.jpg (GRAPHIC) — 194KB
• g821336g37a01.jpg (GRAPHIC) — 32KB
• g821336g41g41.jpg (GRAPHIC) — 173KB
• g821336g41j07.jpg (GRAPHIC) — 146KB
• g821336g48g48.jpg (GRAPHIC) — 64KB
• g821336g61i92.jpg (GRAPHIC) — 151KB
• g821336g69p26.jpg (GRAPHIC) — 120KB
• g821336g71t91.jpg (GRAPHIC) — 95KB
• g821336g82t28.jpg (GRAPHIC) — 38KB
• g821336g82t29.jpg (GRAPHIC) — 90KB
• g821336g82t30.jpg (GRAPHIC) — 100KB
• g821336g89p15.jpg (GRAPHIC) — 178KB
• g821336g92o32.jpg (GRAPHIC) — 51KB
• 0001193125-24-217265.txt ( ) — 6091KB

Risk Factors

Risk Factors 13 Special Note Regarding Forward-looking Statements 77

Use Of Proceeds

Use Of Proceeds 79 Dividend Policy 81 Capitalization 82

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 87

Business

Business 105 Management 152

Executive Compensation

Executive Compensation 163 Director Compensation 178 Certain Relationships and Related Party Transactions 181 Principal Stockholders 188

Description of Capital Stock

Description of Capital Stock 192 Shares Eligible For Future Sale 198 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders of Common Stock 200

Underwriting

Underwriting 204 Legal Matters 213 Experts 213 Where You Can Find More Information 213 Index to Financial Statements F-1 Through and including, 2024 (the 25 th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of the date on the front cover of this prospectus, regardless of its time delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We own various U.S. federal trademark applications, registered and unregistered trademarks, and trade names including our company name. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and , but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. F

View Full Filing

View this S-1/A filing on SEC EDGAR